.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Accenture
Colorcon
Teva
Queensland Health
Federal Trade Commission
Chubb
QuintilesIMS
Cantor Fitzgerald
US Department of Justice

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,207,125

« Back to Dashboard

Which drugs does patent 8,207,125 protect, and when does it expire?


Patent 8,207,125 protects KYPROLIS and is included in one NDA. There has been one Paragraph IV challenge on Kyprolis.

This patent has sixty-nine patent family members in twenty-four countries.

Summary for Patent: 8,207,125

Title:Compounds for enzyme inhibition
Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.
Inventor(s): Smyth; Mark S. (Foster City, CA), Laidig; Guy J. (Menlo Park, CA)
Assignee: Onyx Therapeutics, Inc. (South San Francisco, CA)
Application Number:13/334,288
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-002Jun 3, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY
Onyx TherapKYPROLIScarfilzomibPOWDER;INTRAVENOUS202714-001Jul 20, 2012RXYesYes► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,207,125

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,207,126Compounds for enzyme inhibition► Subscribe
7,232,818Compounds for enzyme inhibition► Subscribe
8,207,127Compounds for enzyme inhibition► Subscribe
8,207,297Compounds for enzyme inhibition► Subscribe
8,207,124Compounds for enzyme inhibition► Subscribe
8,129,346Compounds for enzyme inhibition► Subscribe
8,324,174Compounds for enzyme inhibition► Subscribe
8,198,270Compounds for proteasome enzyme inhibition► Subscribe
7,491,704Compounds for enzyme inhibition► Subscribe
7,417,042Compounds for enzyme inhibition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,207,125

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
LithuaniaC1781688► Subscribe
Slovenia1781688► Subscribe
Slovenia1745064► Subscribe
Luxembourg93015► Subscribe
Netherlands300805► Subscribe
Norway20070965► Subscribe
Singapore10201701794U► Subscribe
LithuaniaPA2016010► Subscribe
South Korea101544258► Subscribe
South Korea20130080064► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Chinese Patent Office
Teva
Covington
Daiichi Sankyo
Johnson and Johnson
Chubb
Merck
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot